CIPE Centro Internacional de Pesquisa; A.C. Camargo Cancer Center

São Paulo 01509-010

1 studies enrolling now · 2 studies all time

What they study most

EBV Related PTCL, NOS, EBV-Positive DLBCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV-Related Non-Hodgkin Lymphoma, EBV-Related PTLD, Epstein-Barr Virus Associated Lymphoma, Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas — Stopped early